Compare SOLAI Limited (SLAI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SOLAI Limited vs Twist Bioscience Corp — how do they compare? SOLAI Limited trades at $3.72 (market cap $16.69M), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is far larger — about 504.5× SOLAI Limited's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| SLAI | TWST | |
|---|---|---|
Market Cap | $16.69M | $8.42B |
Sector | Technology | Health |
52-Week High | $21.63 | $153.10 |
52-Week Low | $2.74 | $24.16 |
Enterprise Value | $16.33M | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement, showing technical bullish signals despite fundamental challenges. The company reported negative financial metrics including -$33.88M net income and -134.63% net margin for 2025, though it beat Q2 2025 EPS expectations. Recent corporate actions include a 7:1 reverse stock split effective July 2026 and a NYSE delisting notice, creating significant uncertainty for investors.
The outlook remains highly speculative with substantial operational risks offset by low valuation multiples. Investment opportunity exists only for risk-tolerant investors betting on the AI infrastructure turnaround, while delisting proceedings and persistent losses present severe downside risks requiring careful monitoring of corporate developments.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
